title: Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
authors.affiliation: Division of Dermatology Department of Internal Related Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Fukumoto
authors.affiliation: Division of Dermatology Department of Internal Related Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Susumu
authors.initials: S
authors.lastname: Fujiwara
authors.affiliation: Division of Dermatology Department of Internal Related Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Masanobu
authors.initials: M
authors.lastname: Sakaguchi
authors.affiliation: Division of Dermatology Department of Internal Related Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Oka
authors.affiliation: Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Naomi
authors.initials: N
authors.lastname: Kiyota
authors.affiliation: Division of Radiation Oncology Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ejima
authors.affiliation: Division of Surgery Shiso Municipal Hospital 93 Yamasaki-cho Shiso-shi, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakajima
authors.affiliation: Division of Dermatology Department of Internal Related Kobe University Graduate School of Medicine 7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan.
authors.forename: Chikako
authors.initials: C
authors.lastname: Nishigori
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D005770:Gastrointestinal Neoplasms / Q000556:secondary / Q000628:therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D000077594:Nivolumab; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077484:Vemurafenib; D014820:Vitiligo / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D000077594:Nivolumab